Celldex Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 6, 2020 and accepted by EDGAR at Aug 6, 2020, 16:21 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $236.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $3.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $9.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $21.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$11.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$24.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-04-01 to 2020-06-30 | −$228.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | −$228.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$11.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$23.7m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | −$0.50 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | −$1.20 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$23.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $1.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $68.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $209.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $261.4m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $10.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $23.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | $238.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001104659-20-091459. Last ingested by Listed: Nov 5, 2026, 19:04 ET. Listed shows no prices and gives no investment advice.